NEWS
Glance Technologies Inc (OTCMKTS:GLNNF) Reports Second Quarter 2018 Results
Glance Technologies Inc (OTCMKTS:GLNNF) has released its financial report for the second quarter ended May 31, 2018.
The second quarter was a difficult one for the company
In a statement, Desmond Griffin, the CEO of Glance said the second quarter came with a very difficult proxy content, but he thanked the shareholders for being patient and allowing the company to come out of the difficult moment. He added that the company came out of the contest in a much stronger position and is currently focusing on its long-term strategy. The strategy involves building capacity by improving its technologies. The company is also investing in growing an ecosystem of engaged users and merchants. Recently, the company instituted changes in its management as it focuses on embracing cost-effective and result-oriented business practices.
Financial results
During the second quarter, the company reported $229,000 in revenue compared to $127,000 that was reported in the second quarter of 2017. Out of the total revenue, application and service fees was $153,000, marketing revenue was $25,000 and licensing revenue was $51,000. The company has been reporting big fluctuations in its licensing revenue in the last few quarters. This is because a number of licensing agreements quoted large initial payments. These fluctuations are expected to continue in the future as new agreements are signed.
Operating expenses amounted to $3.9 million in Q2 2018, a big improvement from the $1.3 million that was reported in the Q2 2017. The increase in expense is a reflection of improved business in the last one year.
The company incurred $745,000 in software development cost in Q2 2018. This is a rise from the $130,000 in Q2 2017. The increase in the cost was as a result of expansion of software development team as well as the company’s move into the blockchain industry.
Other expenses in Q2 2018 were investor media and corporate communication expenses which amounted to $347,000. This is a big increase from the $150,000 that was reported in Q2 2017. It is however a drop compared to the $2.4 million that was reported in Q1 2018. The company had earlier indicated that it intends to reduce spending in that category.
NEWS
Delta 9 Cannabis Inc. (OTCMKTS: DLTNF) Unveils Vaccination reward Program to Encourage Manitobans to Receive COVID-19 Vaccine
Delta 9 Cannabis Inc. (OTCMKTS: DLTNF) has announced the Delta 9 “Joint for Jabs” program, a vaccination reward program, to encourages residents of Manitoba to receive the two doses of the COVID-19 vaccine to be fully vaccinated.
Delta 9 Cannabis launch rewards program
The program started on June 21, 2021, and people that had received both doses of the COVID-19 vaccine will be eligible to enter the rewards program at its locations in Manitoba. The company employs several Manitobans in the province, and the company hopes to help in the reopening of the local communities.
John Arbuthnot, the company’s CEO, said, “We want to encourage all Manitobans to get vaccinated as soon as possible to help ensure that we can all get back to doing the things we love with our friends and family. Our hope is that the “Joints for Jabs” program will contribute to achieve this objective.”
The rewards program is tiered with prize draws expected to be held monthly. In addition, there are three grand prize draws in which a customer will receive One year of Supply of Cannabis, 20 free joints every month at the company’s stores in Manitoba, and Delta 9 Branded Apparel giveaways.
Delta 9 Cannabis announces expansion to Newfoundland
Recently, the company announced that Oceanic Releaf Inc., its strategic partner, had received five cannabis retail licenses in Labrador and Newfoundland provinces. Delta 9 Cannabis owns a 5% stake in Oceanic’s current retail store and expansion plans and production facility operations.
Arbuthnot said that they are looking forward to expanding their presence in Newfoundland. He said that opening five new Oceanic stores in Newfoundland would enable the company to get insight into customers’ buying preferences to assist in tailoring products for the local market.
Featured
Vapor Group Inc (OTCMKTS:VPOR) Business Model Paying Off As Orders for Isolate CBD Stream In
Vapor Group Inc (OTCMKTS:VPOR) is evidently having a spectacular run following the adoption of a new business model early this year focused on the lucrative CBD industry estimated to be worth well over $16 billion. The company recently secured $80,000 order for its premium CBD isolate bringing the total tally of orders to $600,000 this year alone.
$500,000 in under 3 months
As of April this year, the company had reportedly secured orders totaling about $500,000. In its Q1 2019 earnings, VPOR reported a number of high-profile business deals from reputable names in the industry including White Label liquid and GenCanna global, Inc among others. The company’s biggest purchase order thus far came in May when industry titan, Diamond CBD owned by potNetwork holdings placed a hefty $210,000 order for its bulk CBD isolate.
Vapor bills itself as the provider of industry grade CBD isolate famed for its high potency and purity. The product is developed in the company’s state-of-art manufacturing facilities that utilize sophisticated nanotechnology to deliver a premium end product sought after by industry leaders. The trickling enormous purchase orders are testimony of the product’s unparalleled effectiveness.
Sophisticated manufacturing
The company’s products are manufactured from 100% organic hemp sourced from the best growers in the United States from the states of Colorado, Kentucky, and Oregon. VPOR is constantly researching and experimenting on new processing methods and techniques to stay at par with the industry’s dynamic trends.
VPOR’s President and CEO, David Zinger is confident that the company is on course to becoming the premium suppliers of industry-level CBD isolate. Zinger credits the company’s success to over the past few months to “smart planning and strategizing.” Further, he is optimistic that with the continued sustainable growth, the will be able to provide long-term value to their stakeholders.
Positive trends witnessed in the CBD industry points to a lucrative future for players in the sector including Vapor. Reportedly, 7% of Americans are using CBD products now with the number expected to spike by 10% come 2025.
Medical Marijuana Inc. (OTCMKTS:MJNA) has announced that it has been granted authorization to sell its hemp derived CBD products in Bulgaria.
Medical Marijuana receives authorization for CBD products in Bulgaria
Blake Schroeder the CEO of Kannaway stated that they are delighted to continue paving the way for CBD acceptance in Bulgaria to follow suit with what is happening in the rest of the world. The CEO added that following the authorization they were hoping to position themselves in the Bulgarian market and become leaders in CBD education across Europe.
The authorization means that Kannaway’s goods will be freely sold in Bulgaria and they are equally approved for export. Kannaway VP Alex Grapov said that the company was looking forward to trailblazing the global CBD market as advocates of its benefits. He added that they have met with regulatory bodies to makes sure that the company’s operations are within the purview of the law thus creating an avenue for customers and brand ambassadors.
Publication of CBD research on CIPN in Molecular Sciences Journal
Last week Medical Marijuana announced that its portfolio company Kannalife Inc. (OTCMKTS: KLFE) had published its findings on Chemotherapy-Induced Peripheral Neuropathy in the Molecular Neuroscience Journal. Market Study Report LLC has indicated that the international market for CIPN treatment is expected to exceed $1.88 billion by 2024. Kannalife expects clinical trials for its CBD-like molecule KLS-13019 as a therapeutic treatment for CIPN to commence in the second quarter of 2020.
Medical Marijuana CEO Stuart Titus said that CIPN affects around 30% to 405 of patients undergoing chemotherapy adding that they were pleased to support Kannalife in its research to discover a treatment alternative for such patients.
Kannalife was funded by the National Institute on Drug Abuse to work on the research. The grant permits the research in the development of KLS-13019 in CIPN and drug dependence. Kannalife has the obligation to study important advancements that involve identification of the mechanisms that bring CIPN and the application o0f study results in designing on novel treatment approaches for neuropathic pain and use of the approaches in reducing opioid prescription and opioid abuse.
Trulieve Cannabis Corp (OTCMKTS: TCNNF) Announces a Listening and Education Tour
Medical Marijuana Inc’s (OTCMKTS: MJNA) Subsidiary, HempMeds Brasil, Will Sponsor an Obesity Medicine Symposium
Fire & Flower Holdings Corp’s (OTCMKTS: FFLWF) Subsidiary, Pineapple Express Delivery Inc, Will Offer Delivery in Metro Vancouver
Medipharm Labs Corp (OTCMKTS: MEDIF) Completes a Drug Master File (DMF) For API
Hexo Corp (NASDAQ: HEXO) and Kaos Capital Change Hexo’s Board of Directors
